AMR analyzed survey data from infectious disease specialists and internists as well as hospital patient-level medical data. Sixty to 76 percent of surveyed infectious disease specialists indicated that they use vancomycin as first-line treatment for bloodstream infections, complicated skin and skin structure infections and hospital-acquired pneumonia suspected to or confirmed to involve MRSA.
Results also showed surveyed infectious disease specialists consider sepsis and prosthetic joint infections to be the most difficult-to-treat indications needing novel anti-MRSA therapies. Additionally, patient-level audit data of drug costs and usage reveal high antibiotic costs for sepsis and prosthetic joint infections due to long treatment duration and use of premium-priced antibiotics.
Read the AMR news release about MRSA treatments.
Related Articles About MRSA:
Study: Hospital Employees Display Positive Perceptions Toward MRSA Screening Mandates
Study: Antibiotic Linezolid an Effective Treatment for MRSA Infection
Study: Healthcare Workers May Blame External Factors for MRSA Infections
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
